Predictors of opportunistic illnesses incidence in post combination antiretroviral therapy era in an urban cohort from Rio de Janeiro, Brazil

[1]  M. Doherty,et al.  HIV Drug Resistance. , 2018 .

[2]  N. Ford,et al.  Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. , 2015, The lancet. HIV.

[3]  H. Lane,et al.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.

[4]  R. Salamon,et al.  A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. , 2015, The New England journal of medicine.

[5]  R. Chaisson,et al.  Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  S. MacCarthy,et al.  Making the invisible, visible: a cross-sectional study of late presentation to HIV/AIDS services among men who have sex with men from a large urban center of Brazil , 2014, BMC Public Health.

[7]  I. Bassett,et al.  Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002-2013: a meta-analysis. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  G. Maartens,et al.  Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial , 2014, The Lancet.

[9]  L. Kerr,et al.  What's pregnancy got to do with it? Late presentation to HIV/AIDS services in Northeastern Brazil , 2014, AIDS care.

[10]  F. Lert,et al.  Frequency and correlates of late presentation for HIV infection in France: older adults are a risk group – results from the ANRS-VESPA2 Study, France , 2014, AIDS care.

[11]  R. Amancio,et al.  Trends in AIDS-Defining Opportunistic Illnesses Incidence over 25 Years in Rio de Janeiro, Brazil , 2014, PloS one.

[12]  F. Bozza,et al.  Incidence and Determinants of Severe Morbidity among HIV-Infected Patients from Rio De Janeiro, Brazil, 2000–2010 , 2014, Antiviral therapy.

[13]  Kenneth H Mayer,et al.  Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. , 2014, The Lancet. Infectious diseases.

[14]  Richard G. White,et al.  Ability of preventive therapy to cure latent Mycobacterium tuberculosis infection in HIV-infected individuals in high-burden settings , 2014, Proceedings of the National Academy of Sciences.

[15]  H. Günthard,et al.  Adherence as a Predictor of the Development of Class-Specific Resistance Mutations: The Swiss HIV Cohort Study , 2013, PloS one.

[16]  A. Efron,et al.  Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. , 2013, The Lancet. Infectious diseases.

[17]  S. Cole,et al.  A systematic review and meta-regression of temporal trends in adult CD4(+) cell count at presentation to HIV care, 1992-2011. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  Anne M Johnson,et al.  Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE) , 2013, PLoS medicine.

[19]  A. Pacheco,et al.  Changing Mortality Profile among HIV-Infected Patients in Rio de Janeiro, Brazil: Shifting from AIDS to Non-AIDS Related Conditions in the HAART Era , 2013, PloS one.

[20]  E. Vittinghoff,et al.  Declining incidence of AIDS-defining opportunistic illnesses: results from 16 years of population-based AIDS surveillance , 2013, AIDS.

[21]  R. Chaisson,et al.  Antiretroviral Therapy for Prevention of Tuberculosis in Adults with HIV: A Systematic Review and Meta-Analysis , 2012, PLoS medicine.

[22]  Richard D Moore,et al.  Immune Status at Presentation for HIV Clinical Care in Rio de Janeiro and Baltimore , 2011, Journal of Acquired Immune Deficiency Syndromes.

[23]  D. Westreich,et al.  Tuberculosis in Patients Receiving Antiretroviral Treatment: Incidence, Risk Factors, and Prevention Strategies , 2011, Journal of acquired immune deficiency syndromes.

[24]  H. Bang,et al.  Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. , 2010, The New England journal of medicine.

[25]  J. Chmiel,et al.  AIDS-defining opportunistic illnesses in US patients, 1994–2007: a cohort study , 2010, AIDS.

[26]  Richard D Moore,et al.  Early mortality and cause of deaths in patients using HAART in Brazil and the United States , 2009, AIDS.

[27]  L. Rodrigues,et al.  Is it better to be rich in a poor area or poor in a rich area? A multilevel analysis of a case-control study of social determinants of tuberculosis. , 2009, International journal of epidemiology.

[28]  R. Chaisson,et al.  Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort , 2009, AIDS.

[29]  L. Myer,et al.  Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa , 2008, AIDS.

[30]  L. Myer,et al.  Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  Richard D Moore,et al.  The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil , 2007, AIDS.

[32]  J. Sackoff,et al.  AIDS-defining opportunistic illnesses in the HAART era in New York City , 2007, AIDS care.

[33]  Melissa R Pfeiffer,et al.  Causes of Death among Persons with AIDS in the Era of Highly Active Antiretroviral Therapy: New York City , 2006, Annals of Internal Medicine.

[34]  C. Pradier,et al.  In the era of highly active antiretroviral therapy, why are HIV‐infected patients still admitted to hospital for an inaugural opportunistic infection? , 2005, HIV medicine.

[35]  H. Waaler.  Tuberculosis and poverty. , 2002, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[36]  J. Margolick,et al.  Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis , 2001, AIDS.

[37]  G. M. Teixeira.  Digressões sobre plano e programa nacional de controle da tuberculose , 1999 .

[38]  S. Levin.  EFFECT OF ISONIAZID PROPHYLAXIS ON INCIDENCE OF ACTIVE TUBERCULOSIS AND PROGRESSION OF HIV INFECTION Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. Lancet. 1993;342: 268–72 , 1993 .

[39]  J. Pape,et al.  Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection , 1993, The Lancet.

[40]  Dr. Ron Short.  Diagnosis? , 1987, The Lancet.

[41]  J. Volmink,et al.  Treatment of latent tuberculosis infection in HIV infected persons. , 2004, The Cochrane database of systematic reviews.